NCT02550847

Brief Summary

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 8, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 16, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2016

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2016

Completed
Last Updated

April 14, 2016

Status Verified

April 1, 2016

Enrollment Period

1.7 years

First QC Date

September 8, 2015

Last Update Submit

April 12, 2016

Conditions

Pancreatic Cancer

Keywords

MR/PETpancreatic cancer

Outcome Measures

Primary Outcomes (1)

  • The tumor recurrence rate after operation at 6 months

    6 months

Secondary Outcomes (1)

  • The overall survival after operation at 6 months

    6 months

Interventions

The imaging biomarkers determined by MR-PETDEVICE

The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will include 100 consecutive patients (around 100 newly diagnosed patients per year at NTUH) presenting with suspect pancreatic cancer for treatment.

You may qualify if:

  • Diagnosed as pancreatic cancer
  • Between 20\~90 years old
  • ECOG 0-2
  • Normal renal function
  • Measurable tumor size (\>1cm)

You may not qualify if:

  • Contraindication for MRI exam
  • Claustrophobia
  • Renal insufficiency
  • Other malignancy
  • Pregnancy and lactating women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, Taiwan

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System Diseases

Study Officials

  • Ting-Fang Shih, MD

    Department of Medical Imaging, National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ting-Fang Shih, MD

CONTACT

+886-2-23123456ttfshih@ntu.edu.tw

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 8, 2015

First Posted

September 16, 2015

Study Start

August 1, 2014

Primary Completion

April 1, 2016

Study Completion

August 1, 2016

Last Updated

April 14, 2016

Record last verified: 2016-04

Locations

TW(1)